Clinical Trial

Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

Study acronym: ADOPT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-03-06; most recent amendment 2025-04-01.
Status change: Recruiting → Active, Not Recruiting 2025-04-01
Status change: Not Yet Recruiting → Recruiting 2020-08-13
Trial Details
NCT Number NCT04302454
Lead Sponsor University Medical Center Groningen
Collaborators: Dutch Cancer Society
Conditions Prostate Cancer
Enrollment 280 participants
Start Date 2020-03-19
Primary Completion 2027-10-21 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-04